Scorpius Holdings, Inc. (OTC: SCPX), a biomanufacturing company dedicated to advancing therapeutic production capabilities, today announced a comprehensive corporate update highlighting key strategic developments, operational streamlining efforts, and potential global expansion opportunities.

As part of its commitment to long-term value creation, Scorpius Holdings has undertaken a series of cost optimization initiatives aimed at aligning the company’s operational structure with its growth ambitions. These efforts include the reduction of non-essential expenditures, workforce realignment, and increased emphasis on automation and lean manufacturing practices within its operations in San Antonio, Texas.

“2025 is a transformative year for Scorpius,” said Hanad Ahmed, CEO of Scorpius Holdings. “We are taking decisive steps to focus on our core strengths in biomanufacturing while pursuing new opportunities that align with our global vision—especially in fast-growing markets like Southeast Asia.”

The company also announced that it is evaluating strategic partnerships and expansion opportunities in Southeast Asia, a region experiencing rapid growth in biotechnology and pharmaceutical demand. Scorpius is in the early stages of engagement with potential regional stakeholders and views the expansion as a promising avenue to extend its CDMO services to a broader international client base.

Other notable developments include:

• Continued client onboarding in the biologics and advanced therapies space.

• Optimizing internal processes to reduce manufacturing timelines and increase client satisfaction.

• Evaluating strategic alternatives to enhance shareholder value, including M&A opportunities and potential uplisting to a national securities exchange.

The company remains committed to its mission of accelerating access to high-quality biomanufacturing solutions and fostering innovation in biologics production.